Business Description
Keros Therapeutics Inc
NAICS : 325412
SIC : 2833
ISIN : US4923271013
Total Employee Number:
92Description
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 16.38 | |||||
Equity-to-Asset | 0.91 | |||||
Debt-to-Equity | 0.06 | |||||
Debt-to-EBITDA | -0.16 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 2.61 | |||||
Beneish M-Score | -4.53 | |||||
WACC vs ROIC | ||||||
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 72.58 | |||||
9-Day RSI | 65.4 | |||||
14-Day RSI | 61.03 | |||||
3-1 Month Momentum % | -10.1 | |||||
6-1 Month Momentum % | -33.9 | |||||
12-1 Month Momentum % | -31.84 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 21.96 | |||||
Quick Ratio | 21.96 | |||||
Cash Ratio | 21.2 | |||||
Days Sales Outstanding | 197.24 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 10.8 | |||||
Shareholder Yield % | 0.95 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -675.82 | |||||
Net Margin % | -553.88 | |||||
EBITDA Margin % | -665.17 | |||||
FCF Margin % | -322.95 | |||||
OCF Margin % | -319.65 | |||||
ROE % | -18.39 | |||||
ROA % | -17.06 | |||||
ROIC % | -279.86 | |||||
3-Year ROIIC % | 1472.85 | |||||
ROC (Joel Greenblatt) % | -412.82 | |||||
ROCE % | -21.74 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 395.79 | |||||
PS Ratio | 30.38 | |||||
PB Ratio | 0.88 | |||||
Price-to-Tangible-Book | 0.88 | |||||
EV-to-EBIT | 0.1 | |||||
EV-to-EBITDA | 0.1 | |||||
EV-to-Revenue | -0.69 | |||||
EV-to-Forward-Revenue | 0.2 | |||||
EV-to-FCF | 0.21 | |||||
Price-to-GF-Value | 0.86 | |||||
| Price-to-Net-Current-Asset-Value | 0.96 | |||||
| Price-to-Net-Cash | 1 | |||||
Earnings Yield (Greenblatt) % | 1000 | |||||
FCF Yield % | -20.94 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:KROS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Keros Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 15.014 | ||
| EPS (TTM) ($) | -3.7 | ||
| Beta | 1.5966 | ||
| 3-Year Sharpe Ratio | -0.26 | ||
| 3-Year Sortino Ratio | -0.34 | ||
| Volatility % | 42.18 | ||
| 14-Day RSI | 61.03 | ||
| 14-Day ATR ($) | 0.548109 | ||
| 20-Day SMA ($) | 10.61725 | ||
| 12-1 Month Momentum % | -31.84 | ||
| 52-Week Range ($) | 9.69 - 22.55 | ||
| Shares Outstanding (Mil) | 19.83 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Keros Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Keros Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-05 | In 71 days | ||
| Second quarter earnings results for 2026 | 2026-08-03 | 10.07 (-1.37%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-08 16:00 | 10.30 (-4.45%) | ||
| General meeting for 2026 | 2026-06-03 11:00 | 10.55 (-3.74%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 11.99 (+3.54%) | ||
| Leerink Partners Global Healthcare Conference | 2026-03-10 13:00 | 11.35 (+3.65%) | ||
| Annual report for 2025 | 2026-03-04 | 13.40 (-2.90%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-04 | 13.40 (-2.90%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-03 09:50 | 13.91 (-0.64%) | ||
| Oppenheimer 36th Annual Healthcare Life Sciences Conference | 2026-02-25 11:20 | 15.52 (-1.02%) |
Show
Entries
Keros Therapeutics Inc Frequently Asked Questions
What is Keros Therapeutics Inc(KROS)'s stock price today?
The current price of KROS is $11.69. The 52 week high of KROS is $22.55 and 52 week low is $9.69.
When is next earnings date of Keros Therapeutics Inc(KROS)?
The next earnings date of Keros Therapeutics Inc(KROS) is 2026-11-05 Est..
Does Keros Therapeutics Inc(KROS) pay dividends? If so, how much?
Keros Therapeutics Inc(KROS) does not pay dividend.
Guru Commentaries on NAS:KROS
Tidefall Capital Management
Bullish
2025 Q1
8a849d 7ee4eebfc04c41058d734593294ca277
What the manager wrote
We acquired Keros Therapeutics under $10, despite the company having over $14 per share in net cash, and $12 per share in probability weighted discounted milestone/royalty payments. This presents a compelling risk-reward payoff, especially with the recent increase in ownership by ADAR1 Capital Management, which enhances the likelihood of a shareholder friendly outcome.
Press Release
Articles on Keros Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers